Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | Precision epigenetic therapy for B-cell lymphoma

Ari Melnick • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Ari Melnick, MD, Weill Cornell Medical College, New York, NY, discusses precision epigenetic therapy for B-cell lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Ari Melnick

The critical role of SIRT3 in lymphomagenesis
3:59
The critical role of SIRT3 in lymphomagenesis
Ari Melnick • 20 Jun 2019
Epigenetic alleles: an emerging concept
2:45
Epigenetic alleles: an emerging concept
Ari Melnick • 25 Feb 2019
Translating epigenetic therapy to the clinic: rational combinations
5:24
Translating epigenetic therapy to the clinic: rational combinations
Ari Melnick • 24 Feb 2019
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
8:13
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Ari Melnick • 2 Mar 2018

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Ari Melnick • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Ari Melnick • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Ari Melnick • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Ari Melnick • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals